Trial Profile
An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Peginterferon beta-1a (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Sponsors Biocad
- 06 Sep 2021 Status changed from active, no longer recruiting to completed.
- 16 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 07 Sep 2017 Phase of the trial changed from 2 to 2/3.Number of armas has cganged from 3 to4,hence number of planned patient has also changd from 165 to 399.